Introduction
============

Aurora-A was discovered in a screen for Drosophila mutations affecting the poles of the mitotic spindle function [@B1]. Transcription of the Aurora-A gene is cell-cycle regulated. Thus, the promoters of the Aurora-A gene contain specific elements (CDE/CHR sequences), which are responsible for transcription at G2 phase of the cell cycle [@B2]-[@B4]. It has been well documented that activation of Aurora-A is required for mitotic entry, centrosome maturation and separation, and G2 to M transition \[5.6\]. Interestingly, overexpression of Aurora-A is frequently observed in varieties of human cancer, including breast, colorectal, bladder, pancreatic, gastric, ovarian and esophageal cancer [@B7]-[@B12]. Overexpression of Aurora-A in fibroblasts resulted in cell transformation, supporting a notion that high levels of this protein are correlated to cell malignancy [@B13].

Potential roles of Aurora-A in cell transformation were also demonstrated from recent studies that this kinase phosphorylates a breast cancer tumor suppressor BRCA1 at Ser308 [@B14]. Both proteins are localized on centrosome at the beginning of mitosis [@B15], suggesting that signaling between these two proteins are crucial for regulation of normal cell cycle.

Recent studies added a couple of new insight of how Aurora-A induces cell transformation. Thus, in physiological conditions, Aurora-A and its activator collaborate with Plk1, Polo-like kinase 1, to initiate mitosis. On the other hand, in cells transformed with Aurora-A, mTOR pathway is activated [@B16],[@B17].

In this review, differential roles of Aurora-A in cell cycle and cell transformation are discussed.

Aurora-A and BRCA1
==================

The *Aurora-A* gene locus is located in the 20q13 chromosome region, which is frequently amplified in several different types of malignancies such as breast, colorectal, pancreatic, and bladder cancers [@B7]-[@B12]. In particular, 20q11-q13 regions are amplified in 40% of breast cancer cell lines as well as in 12-18% of primary tumors. Aurora-A protein is a member of the Ser/Thr kinase family, and recent studies have shown that the protein is involved in the G2-M checkpoint and commitment to mitosis [@B18]-[@B21]. Furthermore, it has been demonstrated that Aurora-A is inactivated by DNA damage at the end of the G2 phase, and overexpression of Aurora-A abrogates the G2 checkpoint, resulting in the amplified centrosome and cell transformation [@B18]. Significantly, Aurora-A is recruited to the centrosome early in the G2 phase and becomes phosphorylated and activated in the centrosome late in the G2 phase [@B6].

Deng\'s lab demonstrated that \~25% of mouse embryonic fibroblasts (MEFs) derived from the *BRCA1* exon 11-deleted mice contains more than two centrosomes, leading to loss of the G2-M checkpoint and aneuploidy [@B21]. In addition, we and others found that BRCA1 is localized in the centrosome and binds to γ-tubulin [@B15],[@B22],[@B23].

From these observations, we discovered that BRCA1 functionally interacts with Aurora-A [@B14]. Interestingly, the aa1314-1863 region of BRCA1 was found to bind to Aurora-A directly. Mutagenic analysis and phospho-specific antibodies revealed that S308 of BRCA1 is normally phosphorylated by Aurora-A early in the M phase. Phosphorylation of BRCA1 S308 by Aurora-A was abolished by treating cells with ionizing radiation. Most interestingly, re-expression of the phospho-deficient form of BRCA1, S308N (N=Asn), in BRCA1-mutated MEFs resulted in growth arrest at the G2 phase without any cell stress, indicating that phosphorylation of BRCA1 S308 is necessary for the transition from G2 to M. These results indicate that an unphosphorylated form of BRCA1 at S308 is necessary for G2-M checkpoint. These are the first indications of the roles of the physiological levels of BRCA1 phosphorylation in regulating the cell cycle. Additional evidence of BRCA1/Aurora-A interaction is that Aurora-A regulates inhibition of centrosome microtubule nucleation mediated by BRCA1\'s E3 ligase activity [@B24].

Exogenous overexpression of Aurora-A in human cell culture was further studied by transfecting U2OS osteosarcome cell line [@B17]. Interestingly, in those cells, increased phosphorylation of BRCA1 S308 was not detected \[unpublished results\]. These results suggest that phosphorylation of BRCA1 S308 may not be necessary for cell transformation. Thus, perhaps there is substrate selectivity by Aurora-A in physiological and malignant conditions.

Aurora-A and mTOR
=================

Most prominent discoveries from MMTV-Aurora-A transgenic mice are constitutive phosphorylation of mTOR Ser2448 and Akt Ser473 in developed mammary tumors [@B16]. Mammalian target of rapamycin (mTOR) is a protein serine/threonine kinase that controls a broad range of cellular processes. mTOR exists in two distinct complexes; mTOR complex 1 (mTORC1) and complex 2 (mTORC2). mTOR is phosphorylated at multiple sites, including Ser2448, Ser2481, Thr2446 and Ser1261. Phosphorylation at Ser2448 is mediated by p70 ribosomal S6 kinase (S6K) and occurs predominantly to mTOR in mTORC1 [@B25]-[@B27]. mTORC1 is composed of mTOR, mLST8, raptor and PRAS40. Its function is involved in many growth-related processes such as translation, ribosome biogenesis, transcription, autophagy and hypoxic adaptation, and is sensitive to rapamycin. mTORC2 shares both mTOR and mLST8 with mTORC1. Other unique components in mTORC2 are rapamycin-insensitive companion of mTOR (rictor), mammalian stress-activated protein kinase-interacting protein 1(mSIN1) and proline-rich repeat protein-5 (PRR5) or PRR5-like [@B28]-[@B33].

Two major functions have been ascribed to mTORC2, including regulation of Akt and cell cycle-dependent organization of actin cytoskeleton. mTORC2 phosphorylates Akt at Ser473 in its C-terminal hydrophobic motif, which, in conjunction with PDK1-mediated phosphorylation of Thr308, confers full activation of Akt [@B34]. mTORC2 regulates actin cytoskeleton through a mechanism that involves the small GTPases Rho and Rac, although the molecular details are largely still unclear [@B8],[@B35]. Interestingly, mTORC2 phosphorylates PKC and SGK1 (serum- and glucocorticoid-induced protein kinase 1), and has been implicated in controlling cell size [@B36]-[@B39].

Elevated phosphorylation of mTOR Ser2448 and Akt Ser473 in Aurora-A transformed cells suggests that Aurora-A can potentially regulate two mTOR pathways, mTORC1 and mTORC2. Since chemical inhibitors of mTOR can abolish transformed phenotypes induced by Aurora-A [@B17], it is likely that either or both of mTORC1 and 2 is important for Aurora-A transformation.

Of note, mammary tumor development can be observed only after long latency in MMTV-Aurora-A mice [@B16]. In cell culture system of stable transfectants, cells in early passage numbers do not contain phosphorylated mTOR and Akt, but cells after long passage numbers they show up [@B17]. As one possible interpretation, overexpression of Aurora-A is not a strong driving force, but some additional events need to happen to accelerate Aurora-A\'s tumor development. When mTOR pathway is activated under this situation, cells now acquire the full-transforming ability.

Aurora-A and Plk1
=================

Expression of Plk1 is cell cycle-dependent. Levels of the protein increases in late G2 phase, and decreases during mitotic exit [@B40]. Kinase activity well correlates with levels of the protein, thus it increases at G2/M transition and reaches at the maximal during mitosis. Similar to Plk1, levels of Aurora-A increase during G2 and reach at the maximal in early mitosis [@B13],[@B41]. \'Activator\' proteins for Aurora-A have been identified. Those include TPX2, Ajuba, PAK1, HEF1 and hBora [@B6],[@B42]-[@B47]. Among these Aurora-A interactors, hBora expression peaks during G2 and decreases rapidly during mitosis [@B48],[@B49]. It has also been shown that hBora forms a complex with Plk1 in G2 phase [@B48],[@B50],[@B51]. Aurora-A\'s binding to Bora and its subsequent phosphorylation are required for full activation of Aurora-A. In addition, both proteins are essential for Plk1 activation at the centrosome in G2 phase. In this model, it is thought that Bora binding to Plk1 induces allosteric effects that allow Aurora-A to the Plk1 T-loop of its kinase domain, where Aurora-A phosphorylates Thr210, leading to full activation of Plk1 [@B51],[@B52].

It has been speculated that Aurora-A is a target for ubiquitination by CHFR, [ch]{.ul}eckpoint with [F]{.ul}HA and [R]{.ul}ING finger domains. CHFR regulates an early mitotic checkpoint, during prophase, in response to the disruption of microtubule formation or stabilization as assessed after treatment with microtubule inhibitors such as nocodazole, colcemid and taxanes [@B53]. Interestingly, Aurora-A was overexpressed in CHFR-null mouse embryonic fibroblasts and tissues, strongly supporting that CHFR ubiquitinates Aurora-A [@B54]. These studies have also demonstrated that the C-terminal cysteine-rich region of CHFR protein interacts with the N-terminus of Aurora-A protein. Similar results were shown from the other studies that siRNA-mediated depletion of CHFR in MCF10A cells resulted in overexpression of Aurora-A [@B55]. It has been demonstrated that, in HCT116 cells overexpressing CHFR, there was no change in levels of Aurora-A and localization of Aurora-A to the centrosomes, however, nocodazole-induced CHFR-mediated mitotic delay was associated with unphosphorylation of Aurora-A at Thr288 [@B56].

Studies of CHFR protein further supported functional interaction between Aurora-A and Plk1. It has been shown that overexpression of CHFR mutants which mimic unphosphorylated CHFR can decrease levels and kinase activity of Plk1 [@B57]. Interestingly, mouse embryonic fibroblasts from CHFR knockout mice express high levels of Plk1, suggesting that CHFR can ubiquitinate Plk1 to target it for degradation [@B54].

CONCLUSION
==========

Given the high frequency of overexpression of Aurora-A in human cancers, inhibition of Aurora-A with small compounds looks like an attractive cancer-therapeutic strategy. Several compounds have been synthesized and are under clinical trials.

Classical cell biology assay, such as transfection of normal fibroblasts with Aurora-A cDNA, resulted in cell transformation. Transgenic model targeting Aurora-A in mammary glands also support a notion that this kinase is oncogenic. However, quite long latency and low incidence of tumor development in these mice suggest that Aurora-A alone is not a strong driving force of malignancy, but other hits need to occur for full transformation [@B16]. Thus, it is possible that inhibition of Aurora-A with compounds may not be sufficient for killing Aurora cancer cells. Chromosome instabilities observed in those mammary tumors support this hypothesis that activation or inactivation of \'effector proteins\' due to the gross alteration of chromosome structure may result in accelerating tumorigenesis (Fig. [1](#F1){ref-type="fig"}). In that sense, simultaneous inhibition of this pathway(s) as well as Aurora-A might be necessary for the better treatment of patients. For example, mTOR/Akt pathway might be the one which is crucial for Aurora-A tumorigenesis.

I would like to thank members of the Ouchi laboratory and Michael Meyer for critical reading and suggestions. Supported by the NIH (CA79892 and CA90631), Susan G. Komen Foundation and AVON foundation.

![Model of Aurora-A cell transformation. Physiological regulation of Aurora-A kinase activity is by BRCA1, hBora, Ajuba, TPX2 an dPlk1 etc, however, cell transformation by Aurora-A requires additional oncogenic events, such as constitutive activation of mTOR/Akt pathway and loss of PTEN tumor suppressor [@B17].](ijbsv05p0758g01){#F1}

[^1]: Conflict of Interest: The authors have declared that no conflict of interest exists.
